Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Lung Cancer

Volumn 73, Issue 2, 2011, Pages 195-202

  Zhao, Qiong ^a   Shentu, Jianzhong ^a   Xu, Nong ^a   Zhou, Jianya ^a   Yang, Guangdie ^a   Yao, Yinan ^a   Tan, Fenlai ^b   Liu, Dongyang ^c   Wang, Yingxiang ^b   Zhou, Jianying ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang Beta Pharma Inc   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Adverse events; Anti tumor activity; Epidermal growth factor receptor; Erlotinib; Gefitinib; Icotinib hydrochloride; Non small cell lung cancer; Pharmacokinetics; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BPI 2009H; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HEMOGLOBIN; ICOTINIB; K RAS PROTEIN; LIVER ENZYME; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; FEMALE; FOLLICULITIS; GENE MUTATION; GLUCOSE URINE LEVEL; HEMATURIA; HERPETIC WHITLOW; HUMAN; INSOMNIA; JOINT SWELLING; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECTUM CANCER; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH DISCOMFORT; THROAT IRRITATION; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; FEMALE; FOLLICULITIS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79960035905     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.11.007     Document Type: Article

References (34)

1. Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007, 298:70-82.
2. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
3. Press M.F., Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007, 67:2045-2075.
4. Sedlacek H.H. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000, 59:435-476.
5. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
6. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7:1850-1855.
7. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
8. Wang K.L., Wu T.T., Choi I.S., Wang H., Resetkova E., Correa A.M., et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007, 109:658-667.
9. Gibault L., Metges J.P., Conan-Charlet V., Lozac'h P., Robaszkiewicz M., Bessaguet C., et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005, 93:107-115.
10. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28:S24-S31.
11. Stinchcombe T.E., Socinski M.A. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:233-241.
12. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
13. Makris D., Scherpereel A., Copin M.C., Colin G., Brun L., Lafitte J.J., et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007, 7:150.
14. Eskens F.A., Mom C.H., Planting A.S., Gietema J.A., Amelsberg A., Huisman H., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 98:80-85.
15. Erlichman C., Hidalgo M., Boni J.P., Martins P., Quinn S.E., Zacharchuk C., et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006, 24:2252-2260.
16. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369-385.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
18. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001, 92:2639-2647.
19. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
20. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002, 20:3815-3825.
21. Liu D., Jiang J., Hu P., Tan F., Wang Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:3781-3786.
22. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
23. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
24. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(3 Pt 1):839-844.
25. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
26. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
27. Zhu J.Q., Zhong W.Z., Zhang G.C., Li R., Zhang X.C., Guo A.L., et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 2008, 265:307-317.
28. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
29. Toyooka S., Soh J., Shigematsu H., Aoe M., Date H. The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemother Pharmacol 2006, 58:s25-s31.
30. Kosaka T., Yatabe Y., Onozato T., Mitsudomi T. Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma. J Clin Oncol 2007, 25(Suppl.):7574.
31. Shepherd F.A., Tsao M.S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006, 24:1219-1220. author reply 20-1.
32. Toyooka S., Takano T., Kosaka T., Hotta K., Matsuo K., Ichihara S., et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008, 99:303-308.
33. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
34. Suehisa H., Toyooka S., Hotta K., Uchida A., Soh J., Fujiwara Y., et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 2007, 25:3952-3957.